# Enhanced CD56 Expression and Increased Number of CD56+bright Cells in the Peripheral Blood of Untreated Endometriosis Patients

**Authors:** Emma Björk, Pernilla Israelsson, Olga Nagaeva, Lucia Mincheva‐Nilsson, Ulrika Ottander

PMC · DOI: 10.1111/aji.70214 · 2026-02-04

## TL;DR

Untreated endometriosis patients have more CD56+bright NK cells in their blood, which may help diagnose the condition.

## Contribution

The study identifies elevated peripheral CD56+bright NK cells as a potential diagnostic marker for endometriosis.

## Key findings

- Untreated endometriosis patients show increased CD56+bright NK cells compared to controls.
- NKG2D receptor expression is reduced in untreated patients but normalizes with treatment.
- CD56+bright NK cells may migrate from ectopic tissue and impair cytotoxic function.

## Abstract

NK‐cell dysfunction in endometriosis is suggested to contribute to the survival of ectopic endometrial tissue. However, the underlying causes of this impairment remain unclear. NK cells are divided into: CD56+bright, which produce high amounts of cytokines but have low or no cytotoxic ability, and CD56+dim, which are mainly cytotoxic. CD56+bright NK cells, constitutively present in human endometrium (eNK cells), represent only 0–2% of NK cells in PBMC, where CD56+dim cells dominate.

NK‐cell subpopulations and NKG2D receptor expression in PBMC were analyzed by flow cytometry in two cohorts of untreated and treated endometriosis patients and healthy age‐matched controls.

Elevated numbers of CD56+bright cells were observed in 8 of 21 untreated endometriosis patients compared to controls. These numbers were normalized following surgery and hormonal treatment. The NKG2D receptor expression was reduced in untreated patients compared to controls and treated patients.

The significantly increased proportion of peripheral CD56+bright NK/eNK cells may result from migration of these cells from ectopic endometrial tissue. The downregulation of NKG2D receptor expression in PBMCs may be mediated by immunosuppressive endometriotic exosomes, as previously reported by us. Taken together, our results suggest that: (1) the impaired NK cell cytotoxicity in untreated endometriosis patients may be due both to an influx of CD56+bright/eNK cells and exosome‐induced NKG2D receptor downregulation; and (2) elevated numbers of peripheral CD56+bright NK cells could be considered as a potential diagnostic marker for endometriosis.

## Linked entities

- **Proteins:** KLRK1 (killer cell lectin like receptor K1)
- **Diseases:** endometriosis (MONDO:0005133)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CD14 (CD14 molecule) [NCBI Gene 929], IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, KLRB1 (killer cell lectin like receptor B1) [NCBI Gene 3820] {aka CD161, CLEC5B, NKR, NKR-P1, NKR-P1A, NKRP1A}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, KLRD1 (killer cell lectin like receptor D1) [NCBI Gene 3824] {aka CD94}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}
- **Diseases:** cancer (MESH:D009369), malignant melanoma (MESH:D008545), cytotoxicity (MESH:D064420), Endometriosis (MESH:D004715), rASRM stage III and IV (MESH:D062706), dysmenorrhea (MESH:D004412), endometrial lesions (MESH:D014591), endometriotic lesions (MESH:D009059), pain (MESH:D010146), chronic inflammation (MESH:D007249), ovarian endometriomas (MESH:D010049), infertility (MESH:D007246), immune dysfunction (MESH:D007154), III (MESH:C537189)
- **Chemicals:** DACO (-), NA (MESH:D012964), Alexa Fluor 647 (MESH:C569686), heparin (MESH:D006493), PBS (MESH:D007854), MPA (MESH:D017258), HEPES (MESH:D006531), sodium azide (MESH:D019810), levonorgestrel (MESH:D016912), FITC (MESH:D016650)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** RPE — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_4388)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12873557/full.md

---
Source: https://tomesphere.com/paper/PMC12873557